cme.medlearning.de - CME Logo

Literatur

  1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
  2. O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N.Engl.J.Med. 356 (4):348-359, 2007.
  3. O. A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, and R. Herbrecht. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin.Infect.Dis. 44 (10):1289-1297, 2007.
  4. E. R. Kuse, P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (9572):1519-1527, 2007.
  5. A. C. Reboli, C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. Anidulafungin versus fluconazole for invasive candidiasis. N.Engl.J.Med. 356 (24):2472-2482, 2007.
  6. J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, B. van der Hoven, P. Spronk, G. Masterson, M. Malbrain, M. Aoun, J. Garbino, J. Takala, L. Drgona, J. Burnie, R. Matthews, and for the Mycograb Invasive Candidiasis Study Group. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clinical Infectious Diseases 42 (10):1404-113, 2006.
  7. T. J. Walsh, R. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. Greenberg, S. Dummer, M. Schuster, J. Holcenberg, and for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N.Engl.J.Med. 340:764-771, 1999.
  8. T. J. Walsh, P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, and J. Lee. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent Fever. N Engl J Med 2002 Jan 24;346(4):225-34., 2002.
  9. T. J. Walsh, H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, and B. E. dePauw. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N.Engl.J.Med. 351 (14):1391-1402, 2004.
  10. J. R. Wingard, M. H. White, E. Anaissie, J. Raffalli, J. Goodman, A. Arrieta, and L. Amph and the. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clinical Infectious Diseases 31 (5):1155-1163, 2000.
  11. D. J. Winston, J. W. Hathorn, M. G. Schuster, G. J. Schiller, and M. C. Territo. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. American Journal of Medicine 108 (4):282-29, 2000.
  12. M. Boogaerts, D. J. Winston, E. J. Bow, G. Garber, A. C. Reboli, A. P. Schwarer, N. Novitzky, A. B”hme, E. Chwetzoff, K. De Beule, and Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 Sep 18;135(6):412-22., 2001.
  13. Marr KA, Boeckh M, Carter RA, Kim HJ, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
  14. J. Maertens, A. Glasmacher, R. Herbrecht, A. Thiebaut, C. Cordonnier, B. H. Segal, J. Killar, A. Taylor, N. Kartsonis, T. F. Patterson, M. Aoun, D. Caillot, and C. Sable. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107 (12):2888-2897, 2006.
  15. L. J. Wheat. Combination therapy for aspergillosis: is it needed, and which combination? The Journal of Infectious Diseases 187 (12):1831-183, 2003.
  16. F. Menichetti, A. Del Favero, P. Martino, G. Bucaneve, A. Micozzi, C. Girmenia, G. Barbabietola, L. Pagano, P. Leoni, G. Specchia, A. Caiozzo, R. Raimondi, and F. Mandelli. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clinical Infectious Diseases 28 (2):250-255, 1999.
  17. A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G. Schmidt-Wolf. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J.Clin.Oncol. 21 (24):4615-4626, 2003
  18. J. L. Goodman, D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, and D. J. Friedman. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation [see comments]. N.Engl.J.Med. 326 (13):845-851, 1992.
  19. O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N.Engl.J.Med. 356 (4):348-359, 2007.
  20. A. J. Ullmann, J. H. Lipton, D. H. Vesole, P. Chandrasekar, A. Langston, S. R. Tarantolo, H. Greinix, Azevedo W. Morais de, V. Reddy, N. Boparai, L. Pedicone, H. Patino, and S. Durrant. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N.Engl.J.Med. 356 (4):335-347, 2007.
  21. J. Ullmann and O. A. Cornely. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr.Opin.Infect.Dis. 19 (6):571-576, 2006.
  22. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microb Rev 2005; 18: 44-69.
  23. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407.
  24. L. Ostrosky-Zeichner, K. A. Marr, J. H. Rex, and S. H. Cohen. Amphotericin B: time for a new "gold standard". Clin.Infect.Dis. 37 (3):415-425, 2003.
  25. D. W. Bates, L. Su, D. T. Yu, G. M. Chertow, D. L. Seger, D. R. J. Gomes, E. J. Dasbach, and R. Platt. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 Mar 1;32(5):686-93., 2001.
  26. (1) Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407.
  27. (2) Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;26:1406-1412.
  28. (3) Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998;42:2391-2398.
  29. (4) Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22 Suppl 2:S133-144.
  30. (5) Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-1098.
  31. (6) Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
  32. (7) Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-760.
  33. (8) Kruger WH, Kroger N, Russmann B, Renges H, Kabisch H, Zander AR. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B. Bone Marrow Transplant 1998;22 Suppl 4:S10-13.
  34. (9) Leenders AC, Daenen S, Jansen RL, et al. Lipsomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-212.
  35. (10) T. J. Walsh, R. Finberg, C. Arndt, J. Hiemenz, C. Schwartz, D. Bodensteiner, P. Pappas, N. Seibel, R. Greenberg, S. Dummer, M. Schuster, J. Holcenberg, and for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N.Engl.J.Med. 340:764-771, 1999.
  36. (11) O. A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, and R. Herbrecht. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin.Infect.Dis. 44 (10):1289-1297, 2007.
  37. T. J. Walsh, P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob.Agents Chemother. 49 (11):4536-4545, 2005.
  38. S. C. Deresinski and D. A. Stevens. Caspofungin. Clinical Infectious Diseases 36 (11):1445-157, 2003.